Last reviewed · How we verify
Hyperan (EXALAMIDE)
Hyperan (generic name: EXALAMIDE) is a drug. It is currently in Phase 2 development.
Exalamide works by interacting with a specific molecular target to produce a therapeutic effect.
Exalamide, also known as Hyperan, is a small molecule modality with unknown target and drug class. Its commercial status is unclear, and it is not known if it is FDA approved or off-patent. There is limited information available on its approved indications, half-life, bioavailability, and generic manufacturers. Further research is needed to understand its clinical use and safety profile. As a result, it is not possible to provide a comprehensive summary of its key safety considerations.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | EXALAMIDE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells have locks on them, and the key to unlocking the right response is a specific molecule. Exalamide is designed to fit that key and turn it to help your body respond in a healthy way. This can help to treat various conditions by restoring balance to your body's functions.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hyperan CI brief — competitive landscape report
- Hyperan updates RSS · CI watch RSS
Frequently asked questions about Hyperan
What is Hyperan?
How does Hyperan work?
What is the generic name of Hyperan?
What development phase is Hyperan in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing